Platelet activating factor receptor antagonists improve the efficacy of experimental chemo- and radiotherapy

Platelet activating factor is a lipid mediator of inflammation, and in recent decades, it has emerged as an important factor in tumor outcomes. Platelet activating factor acts by specific binding to its receptor, which is present in both tumor cells and cells that infiltrate tumors. Pro-tumorigenic...

Descripción completa

Detalles Bibliográficos
Autores principales: da Silva Junior, Ildefonso Alves, Andrade, Luciana Nogueira de Sousa, Jancar, Sonia, Chammas, Roger
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo 2018
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6157068/
https://www.ncbi.nlm.nih.gov/pubmed/30328954
http://dx.doi.org/10.6061/clinics/2018/e792s

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6157068/
https://www.ncbi.nlm.nih.gov/pubmed/30328954
http://dx.doi.org/10.6061/clinics/2018/e792s

Ejemplares similares